# Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Study · id `cardio:ct-nct03349840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03349840](<https://clinicaltrials.gov/study/NCT03349840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03349840

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 273 participants.

## Technical summary

Registry record NCT03349840. Randomized; no masking; primary purpose treatment. Start 2018-01-07 (actual); primary completion 2018-08-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 273 participants (enrolled count; ClinicalTrials.gov record NCT03349840, source copy `cardio:ctgov-nct03349840-2020-06-09`, retrieved 2026-10-26)
- Started: 2018-01-07 (actual) (ClinicalTrials.gov record NCT03349840, source copy `cardio:ctgov-nct03349840-2020-06-09`, retrieved 2026-10-26)
- Primary completion: 2018-08-03 (actual) (ClinicalTrials.gov record NCT03349840, source copy `cardio:ctgov-nct03349840-2020-06-09`, retrieved 2026-10-26)
- Completion: 2018-12-31 (actual) (ClinicalTrials.gov record NCT03349840, source copy `cardio:ctgov-nct03349840-2020-06-09`, retrieved 2026-10-26)
- Countries: Qatar (ClinicalTrials.gov record NCT03349840, source copy `cardio:ctgov-nct03349840-2020-06-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03349840-2020-06-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
- Condition: Type2 Diabetes
- Intervention (Drug): Insulin Degludec U100
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Weill Cornell Medical College in Qatar
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Weill Cornell Medical College in Qatar (`cardio:org-weill-cornell-medical-college-in-qatar`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 671e2f8e7782420c730c5f37d8356a056f6f3aa64c607813bcb1a8afbc202970
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
